RA Capital Management

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.

Develops oligonucleotide therapeutics targeting chronic hepatitis B

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease

Develops fungal genome-derived therapeutics for organ transplant rejection